[1]赵娜 符珍珍 兰雨 张锦 马志远.克隆性造血与心血管疾病相关性的研究进展[J].心血管病学进展,2024,(4):355.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.015]
 ZHAO Na,FU Zhenzhen,LAN Yu,et al.Correlation Between Clonal Hematopoiesis and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2024,(4):355.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.015]
点击复制

克隆性造血与心血管疾病相关性的研究进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年4期
页码:
355
栏目:
综述
出版日期:
2024-04-25

文章信息/Info

Title:
Correlation Between Clonal Hematopoiesis and Cardiovascular Disease
作者:
赵娜1 符珍珍 1 兰雨 1 张锦 2 马志远 3
(1.兰州大学第一临床医学院,甘肃 兰州 730000;2.兰州大学第一医院心血管内科 甘肃省心血管疾病重点实验室,甘肃 兰州 730000;3.兰州大学第一医院老年医学科,甘肃 兰州 730000)
Author(s):
ZHAO Na1FU Zhenzhen1LAN Yu1ZHANG Jin2MA Zhiyuan3
(1.The First Clinical Medical College of Lanzhou University,Lanzhou 730000,Gansu,China; 2.Department of Cardiovascular Medicine,The First Hospital of Lanzhou University,Key Laboratory of Cardiovascular Diseases in Gansu Province,Lanzhou 730000,Gansu,China; 3.Department of Geriatrics,The First Hospital of Lanzhou University,Lanzhou 730000,Gansu,China)
关键词:
克隆性造血心血管疾病体细胞突变Y染色体缺失炎症反应
Keywords:
Clonal hematopoiesisCardiovascular diseaseSomatic mutationLoss of Y chromosomeInflammatory reaction
DOI:
10.16806/j.cnki.issn.1004-3934.2024.04.015
摘要:
造血系统中体细胞突变的非恶性克隆扩增被称为克隆性造血,是在驱动基因突变后突变白细胞比例增加的过程。克隆性造血的遗传模式包括白血病驱动基因突变、常染色体镶嵌染色体交替和性染色体缺失。新近研究指出,由白血病驱动基因突变或白细胞Y染色体镶嵌缺失引起的克隆性造血,会影响各种心血管疾病(包括动脉粥样硬化、心力衰竭、心脏纤维化)的发生发展。越来越多的证据表明,克隆性造血是心血管疾病的一种新机制,也是一类新的危险因素,与传统危险因素同等重要。现分析克隆性造血的遗传模式,对其与心血管疾病之间的相关性展开综述分析。
Abstract:
Non-malignant clonal amplification of somatic cell mutation in hematopoietic system is called clonal hematopoiesis,which is a process of increasing the proportion of mutant white blood cells after driving gene mutation. The genetic patterns of clonal hematopoiesis include leukemia driver gene mutation,autosomal mosaic chromosome alternation and sex chromosome deletion. Recent studies have pointed out that clonal hematopoiesis caused by leukemia driver gene mutation or white blood cell Y chromosome mosaic deletion will affect the occurrence and development of various cardiovascular disease (including atherosclerosis,heart failure and cardiac fibrosis). More and more evidence shows that clonal hematopoiesis is a new mechanism of cardiovascular disease and a new kind of risk factor,which is as important as traditional risk factors. Therefore,this paper analyzes the genetic model of clonal hematopoiesis and summarizes the correlation between clonal hematopoiesis and cardiovascular disease

参考文献/References:

[1]Choi D,Malick WA,Koenig W,et al. Familial hypercholesterolemia:challenges for a high-risk population:JACC focus seminar 1/3[J]. J Am Coll Cardiol,2023,81(16):1621-1632.[2]Geisterfer-Lowrance AAT,Kass S,Tanigawa G,et al. A molecular basis for familial hypertrophic cardiomyopathy:a β cardiac myosin heavy chain gene missense mutation[J]. Cell,1990,62(5):999-1006.[3]Chai AC,Cui M,Chemello F,et al. Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice[J]. Nat Med,2023,29(2):401-411.[4]Walsh R,Jurgens SJ,Erdmann J,et al. Genome-wide association studies of cardiovascular disease[J]. Physiol Rev,2023,103(3):2039-2055.[5]Heimlich JB,Bick AG. Somatic mutations in cardiovascular disease[J]. Circ Res,2022,130(1):149-161. [6]Libby P,Sidlow R,Lin AE,et al. Clonal hematopoiesis:crossroads of aging,cardiovascular disease,and cancer:JACC review topic of the week[J]. J Am Coll Cardiol,2019,74(4):567-577.[7]Young AL,Challen GA,Birmann BM,et al. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults[J]. Nat Commun,2016,7(1):12484.[8]Steensma DP,Bejar R,Jaiswal S,et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes[J]. Blood,2015,126(1):9-16.[9]Mitchell E,Spencer Chapman M,Williams N,et al. Clonal dynamics of haematopoiesis across the human lifespan[J]. Nature,2022,606(7913):343-350. [10]Fuster JJ,MacLauchlan S,Zuriaga MA,et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice[J]. Science,2017,355(6327):842-847.[11]Sano S,Horitani K,Ogawa H,et al. Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality[J]. Science,2022,377(6603):292-297. [12]Belizaire R,Wong WJ,Robinette ML,et al. Clonal haematopoiesis and dysregulation of the immune system[J]. Nat Rev Immunol,2023,23(9):595-610. [13]Terao C,Suzuki A,Momozawa Y,et al. Chromosomal alterations among age-related haematopoietic clones in Japan[J]. Nature,2020,584(7819):130-135.[14]Jaiswal S,Natarajan P,Silver AJ,et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease[J]. N Engl J Med,2017,377(2):111-121.[15]Haitjema S,Kofink D,van Setten J,et al. Loss of Y chromosome in blood is associated with major cardiovascular events during follow-up in men after carotid endarterectomy[J]. Circ Cardiovasc Genet,2017,10(4):e001544. [16]Dumanski JP,Rasi C,L?n M,et al. Smoking is associated with mosaic loss of chromosome Y[J]. Science,2015,347(6217):81-83.[17]Ljungstr? V,Mattisson J,Halvardson J,et al. Loss of Y and clonal hematopoiesis in blood—two sides of the same coin?[J]. Leukemia,2022,36(3):889-891.[18]Ouseph MM,Hasserjian RP,Dal Cin P,et al. Genomic alterations in patients with somatic loss of the Y chromosome as the sole cytogenetic finding in bone marrow cells[J]. Haematologica,2021,106(2):555.[19]Zhang Q,Zhao L,Yang Y,et al. Mosaic loss of chromosome Y promotes leukemogenesis and clonal hematopoiesis[J]. JCI insight,2022,7(3):e153768..[20]Genovese G,K?ler AK,Handsaker RE,et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence[J]. N Engl J Med,2014,371(26):2477-2487. [21]Jaiswal S,Fontanillas P,Flannick J,et al. Age-related clonal hematopoiesis associated with adverse outcomes[J]. N Engl J Med,2014,371(26):2488-2498.[22]Sano S,Oshima K,Wang Y,et al. Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 inflammasome[J]. J Am Coll Cardiol,2018,71(8):875-886. [23]B?me M,Desch S,Rosolowski M,et al. Impact of clonal hematopoiesis in patients with cardiogenic shock complicating acute myocardial infarction[J]. J Am Coll Cardiol,2022,80(16):1545-1556. [24]Yu B,Roberts MB,Raffield LM,et al. Association of clonal hematopoiesis with incident heart failure[J]. J Am Coll Cardiol,2021,78(1):42-52.[25]Zeiher A,Braun T. Mosaic loss of Y chromosome during aging[J]. Science,2022,377(6603):266-267.[26]Mas-Peiro S,Abplanalp WT,Rasper T,et al. Mosaic loss of Y chromosome in monocytes is associated with lower survival after transcatheter aortic valve replacement[J]. Eur Heart J,2023,44(21):1943-1952.[27]Dorsheimer L,Assmus B,Rasper T,et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure[J]. JAMA Cardiol,2019,4(1):25-33.[28]Abplanalp WT,Cremer S,John D,et al. Clonal hematopoiesis–driver DNMT3A mutations alter immune cells in heart failure[J]. Circ Res,2021,128(2):216-228.[29]Assmus B,Cremer S,Kirschbaum K,et al. Clonal haematopoiesis in chronic ischaemic heart failure:prognostic role of clone size for DNMT3A-and TET2-driver gene mutations[J]. Eur Heart J,2021,42(3):257-265.[30]Kiefer KC,Cremer S,Pardali E,et al. Full spectrum of clonal haematopoiesis‐driver mutations in chronic heart failure and their associations with mortality[J]. ESC Heart Fail,2021,8(3):1873-1884.[31]Yura Y,Miura-Yura E,Katanasaka Y,et al. The cancer therapy-related clonal hematopoiesis driver gene Ppm1d promotes inflammation and non-ischemic heart failure in mice[J]. Circ Res,2021,129(6):684-698.[32]Sano S,Wang Y,Ogawa H,et al. TP53-mediated therapy-related clonal hematopoiesis contributes to doxorubicin-induced cardiomyopathy by augmenting a neutrophil-mediated cytotoxic response[J]. JCI insight,2021,6(13):e146076..[33]Min KD,Polizio AH,Kour A,et al. Experimental ASXL1-mediated clonal hematopoiesis promotes inflammation and accelerates heart failure[J]. J Am Heart Assoc,2022,11(19):e026154.[34]Zekavat SM,Viana-Huete V,Matesanz N,et al. TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease[J]. Nat Cardiovasc Res,2023,2(2):144-158. Sano S,Thel MC,Walsh K. Clonal hematopoiesis:the nonhereditary genetics of age-associated cardiovascular disease[J]. Curr Opin Cardiol,2023,38(3):201-206.

相似文献/References:

[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
 BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(4):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
 REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(4):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
 YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(4):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
 ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(4):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
 QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(4):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
 JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(4):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
 HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(4):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
 Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(4):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
 WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(4):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]

更新日期/Last Update: 2024-05-31